PURPOSE: Prospective studies suggest that statins protect against advanced stage and possibly high grade prostate cancer. However, few studies have investigated the influence of stains on outcomes in men with prostate cancer. Thus, we evaluated the association of statin use with pathological tumor characteristics and prostate cancer recurrence after prostatectomy in a retrospective cohort. MATERIALS AND METHODS: A total of 2,399 patients of 1 surgeon at Johns Hopkins Hospital who underwent radical prostatectomy in 1993 to 2006 and had not previously received hormone or radiation therapy were followed for recurrence. The surgeon routinely asked during the preoperative consultation what medications the men were using. Additional information on statin use was obtained from a mailed survey. We estimated the association of statin use with nonorgan confined disease (pT3a/b or N1) and high grade disease (Gleason sum [4 + 3] or greater) using logistic regression (OR), and recurrence using Cox proportional hazards regression (HR). RESULTS: The 16.1% of men who used a statin at prostatectomy were statistically significantly less likely to have nonorgan confined disease than nonusers (OR 0.66, 95% CI 0.50-0.85). Statin use was inversely associated with high grade disease only in men with preoperative PSA 10 ng/ml or greater (OR 0.35, 95% CI 0.13-0.93, p-interaction = 0.02). The HR of recurrence among men who used a statin for 1 year or greater compared to nonusers was 0.77 (95% CI 0.41-1.42). CONCLUSIONS: Our findings support the hypothesis that statin use may protect against prostate cancer with poorer pathological characteristics. We could not rule in or out that longer term statin use may protect against recurrence after prostatectomy.
PURPOSE: Prospective studies suggest that statins protect against advanced stage and possibly high grade prostate cancer. However, few studies have investigated the influence of stains on outcomes in men with prostate cancer. Thus, we evaluated the association of statin use with pathological tumor characteristics and prostate cancer recurrence after prostatectomy in a retrospective cohort. MATERIALS AND METHODS: A total of 2,399 patients of 1 surgeon at Johns Hopkins Hospital who underwent radical prostatectomy in 1993 to 2006 and had not previously received hormone or radiation therapy were followed for recurrence. The surgeon routinely asked during the preoperative consultation what medications the men were using. Additional information on statin use was obtained from a mailed survey. We estimated the association of statin use with nonorgan confined disease (pT3a/b or N1) and high grade disease (Gleason sum [4 + 3] or greater) using logistic regression (OR), and recurrence using Cox proportional hazards regression (HR). RESULTS: The 16.1% of men who used a statin at prostatectomy were statistically significantly less likely to have nonorgan confined disease than nonusers (OR 0.66, 95% CI 0.50-0.85). Statin use was inversely associated with high grade disease only in men with preoperative PSA 10 ng/ml or greater (OR 0.35, 95% CI 0.13-0.93, p-interaction = 0.02). The HR of recurrence among men who used a statin for 1 year or greater compared to nonusers was 0.77 (95% CI 0.41-1.42). CONCLUSIONS: Our findings support the hypothesis that statin use may protect against prostate cancer with poorer pathological characteristics. We could not rule in or out that longer term statin use may protect against recurrence after prostatectomy.
Authors: Marie-France Demierre; Peter D R Higgins; Stephen B Gruber; Ernest Hawk; Scott M Lippman Journal: Nat Rev Cancer Date: 2005-12 Impact factor: 60.716
Authors: Mark A Moyad; Gregory S Merrick; Wayne M Butler; Kent E Wallner; Robert W Galbreath; Earnest G Butler; Zachariah A Allen; Edward Adamovich Journal: Urol Nurs Date: 2006-08
Authors: Robert J Hamilton; Lionel L Banez; William J Aronson; Martha K Terris; Elizabeth A Platz; Christopher J Kane; Joseph C Presti; Christopher L Amling; Stephen J Freedland Journal: Cancer Date: 2010-07-15 Impact factor: 6.860
Authors: Søren Friis; Aslak H Poulsen; Søren P Johnsen; Joseph K McLaughlin; Jon P Fryzek; Susanne O Dalton; Henrik T Sørensen; Jørgen H Olsen Journal: Int J Cancer Date: 2005-04-20 Impact factor: 7.396
Authors: L Spencer Krane; Sanjeev A Kaul; Hans J Stricker; James O Peabody; Mani Menon; Piyush K Agarwal Journal: J Urol Date: 2010-01 Impact factor: 7.450
Authors: Byron H Lee; Margaret G Taylor; Peggy Robinet; Jonathan D Smith; Jessica Schweitzer; Ephraim Sehayek; Sara M Falzarano; Cristina Magi-Galluzzi; Eric A Klein; Angela H Ting Journal: Cancer Res Date: 2012-12-11 Impact factor: 12.701
Authors: India Anderson-Carter; Natasza Posielski; Jinn-Ing Liou; Tariq A Khemees; Tracy M Downs; E Jason Abel; David F Jarrard; Kyle A Richards Journal: Urol Oncol Date: 2018-12-07 Impact factor: 3.498
Authors: Milan S Geybels; Jonathan L Wright; Sarah K Holt; Suzanne Kolb; Ziding Feng; Janet L Stanford Journal: Prostate Date: 2013-04-30 Impact factor: 4.104
Authors: Monica N Schointuch; Timothy P Gilliam; Jessica E Stine; Xiaoyun Han; Chunxiao Zhou; Paola A Gehrig; Kenneth Kim; Victoria L Bae-Jump Journal: Gynecol Oncol Date: 2014-05-28 Impact factor: 5.482